Psychedelic Therapy for Addiction: Can Psilocybin, MDMA & Ketamine Treat Alcoholism & Drug Addiction? | Charlotte, NC
Psychedelic-assisted therapy is emerging as one of the most promising—and controversial—breakthroughs in addiction treatment. Clinical trials published in 2024-2025 show that psilocybin (the psychoactive compound in “magic mushrooms”) combined with psychotherapy produced 80% abstinence rates at 6 months for smoking cessation—dramatically outperforming traditional treatments which achieve less than 35% abstinence. For alcohol use disorder, psilocybin reduced heavy drinking by 83% on average. MDMA-assisted therapy for PTSD (which often drives addiction) showed 67% of participants no longer meeting PTSD criteria after treatment. These aren’t fringe studies—they’re rigorous, double-blind, placebo-controlled trials published in leading medical journals and receiving the first U.S. government funding for psychedelic research since the 1971 ban.
At Nova Transformations in Charlotte, North Carolina, we’re closely monitoring this rapidly evolving field while providing evidence-based dual diagnosis treatment that addresses both addiction and underlying trauma. Psychedelic therapy isn’t yet FDA-approved for addiction (MDMA for PTSD may be approved in 2025), and it’s not available at most treatment centers. However, the science is genuinely revolutionary: these substances appear to work on fundamental brain mechanisms underlying addiction, trauma, and rigid thought patterns in ways that traditional medications don’t. By promoting neuroplasticity, processing deep-seated trauma, and creating what researchers call “mystical experiences” that correlate with better outcomes, psychedelics may offer hope for people who haven’t responded to conventional treatments.
This comprehensive guide explains what psychedelic-assisted therapy is, the clinical evidence for treating addiction, how these substances work in the brain, which addictions they may help, legal status in 2025, who should (and shouldn’t) consider them, risks and controversies, and how this emerging approach fits with proven treatments at Nova Transformations in Charlotte.
Abstinence rate at 6 months for smoking cessation with psilocybin-assisted therapy vs. <35% with traditional treatments
What Is Psychedelic-Assisted Therapy?
The Basics
Psychedelic-assisted therapy (PAT) combines controlled administration of psychedelic substances with structured psychotherapy in a clinical setting.
Key components:
- Preparation sessions: Therapy before psychedelic experience to build trust, set intentions
- Dosing session(s): Taking psychedelic in supervised setting with trained therapists present
- Integration sessions: Therapy afterward to process insights and apply to recovery
- Medical supervision: Screening, monitoring vital signs, ensuring safety
- NOT recreational use: Structured, therapeutic protocol with clear goals
Types of Psychedelics Being Studied
Classic Psychedelics (Serotonergic):
- Psilocybin: From “magic mushrooms”—most studied for addiction
- LSD: Lysergic acid diethylamide—used in 1950s-1960s addiction research
- DMT/Ayahuasca: Amazonian plant medicine containing DMT
- Mescaline: From peyote cactus—sacred in Native American traditions
- 5-MeO-DMT: From Sonoran Desert toad—ultra-short-acting
Mechanism: Act as agonists of serotonin 5-HT2A receptor
Non-Classic Psychedelics:
- MDMA: 3,4-methylenedioxymethamphetamine (“Ecstasy”)—empathogenic effects
- Ketamine: Dissociative anesthetic—already used for depression
- Ibogaine: From Iboga plant—studied for opioid withdrawal
Mechanism: Engage different receptor systems (NMDA, kappa-opioid, etc.)
Brief History
1950s-1960s: Golden Age
- Over 1,000 clinical studies on psychedelics
- LSD therapy for alcoholism showed promise
- Thousands of patients treated
- Research by leading institutions
1970: The Dark Ages
- Controlled Substances Act classified LSD, psilocybin as Schedule I
- “High potential for abuse, no medical use”
- Research essentially stopped for 40+ years
- Counter-culture association stigmatized legitimate research
2000s-Present: Renaissance
- Johns Hopkins, Imperial College, NYU restart research
- FDA grants “Breakthrough Therapy” designation
- First government funding since 1971
- Path to FDA approval for MDMA, psilocybin
Reduced risk of opioid dependence associated with psychedelic use in 44,000-person study
The Clinical Evidence: What Do Studies Show?
Psilocybin for Alcohol Use Disorder ⭐⭐⭐⭐⭐
STRONGEST EVIDENCE
Landmark 2022 Study (JAMA Psychiatry):
- Design: Randomized, double-blind, placebo-controlled trial
- Participants: 93 people with alcohol use disorder
- Treatment: 2 doses psilocybin + 12 weeks psychotherapy vs. placebo + therapy
- Results: 83% reduction in heavy drinking days at 32 weeks
- Statistical significance: p<0.001 (highly significant)
- Duration: Benefits sustained through 36-week follow-up
Additional findings:
- Higher “mystical experience” scores correlated with better outcomes
- Significant reduction in craving
- Improved quality of life measures
- Well-tolerated with manageable side effects
Psilocybin for Tobacco/Nicotine Addiction ⭐⭐⭐⭐⭐
Johns Hopkins Study:
- Participants: 15 long-term smokers (averaging 31 cigarettes/day)
- Treatment: Psilocybin + cognitive behavioral therapy
- Results: 80% (12/15) biochemically confirmed abstinence at 6 months
- Comparison: Traditional treatments achieve <35% abstinence at 6 months
- Follow-up: 11/12 quit after FIRST psilocybin session
- Long-term: Benefits sustained at 12 and 30-month follow-ups
Retrospective survey (358 participants):
- 2-5 lifetime uses of psilocybin, LSD, or ayahuasca
- 137 quit smoking completely
- 100 reduced smoking
- 121 stopped but later relapsed
Psilocybin for Cocaine Use Disorder ⭐⭐⭐⭐
University of Alabama Study (ongoing):
- Early results (first 10 patients)
- Higher life satisfaction
- Less depression
- More abstinent days than placebo group
- Full results pending publication
MDMA for PTSD (Driving Addiction) ⭐⭐⭐⭐⭐
MAPS Phase 3 Trials (2021):
- Design: Randomized, double-blind, placebo-controlled
- Results: 67% no longer met PTSD criteria after 3 sessions MDMA + therapy
- Benefits sustained: Months to years after treatment
- FDA status: May be approved for PTSD in 2025
Why this matters for addiction: Trauma is a major driver of substance use disorders. Treating underlying PTSD often dramatically improves addiction outcomes.
LSD for Alcohol Addiction (Historical)
Meta-analysis of 1960s-1970s studies:
- 6 randomized controlled trials
- 536 participants with alcohol use disorder
- Beneficial effect of LSD
- Efficacy comparable to disulfiram (Antabuse)
Ketamine for Multiple Addictions ⭐⭐⭐⭐
- Already FDA-approved for treatment-resistant depression
- Studies ongoing for alcohol, cocaine, opioid use disorders
- Rapid-acting (hours, not weeks)
- Some concerns about abuse potential
Ibogaine for Opioid Addiction ⭐⭐⭐
- Used in underground clinics (primarily Mexico)
- Anecdotal reports of interrupting withdrawal, reducing cravings
- Clinical trials now underway
- Safety concerns: Cardiac risks require medical supervision
Observational Data
44,000-person study:
- People with history of illicit opioid use
- Psychedelic use associated with 27% reduced risk of opioid dependence
✨ What the Evidence Shows
Psychedelic-assisted therapy demonstrates efficacy rates that substantially exceed traditional addiction treatments for alcohol, tobacco, and emerging evidence for cocaine and opioids. The consistency across multiple studies, substances, and research groups suggests real therapeutic potential—not placebo effects or wishful thinking.
How Do Psychedelics Work for Addiction?
1. Neuroplasticity and Brain “Reset”
Psychedelics promote dramatic increases in neuroplasticity—the brain’s ability to form new connections:
- 5-HT2A receptor activation: Classic psychedelics strongly activate serotonin 2A receptors
- BDNF signaling: Promotes brain-derived neurotrophic factor—”fertilizer for the brain”
- Synaptic plasticity: Facilitates new neural pathways, breaking rigid patterns
- Network disruption: Temporarily dissolves entrenched brain networks including addiction circuits
- “Reset” effect: Creates window for new patterns to form
Why this matters: Addiction creates rigid, maladaptive brain circuits. Psychedelics may allow “rewiring.”
2. Trauma Processing
Many addictions are rooted in unprocessed trauma. Psychedelics facilitate deep trauma work:
- MDMA reduces fear response: Allows accessing traumatic memories without overwhelming distress
- Increased emotional openness: Can feel and process repressed emotions
- Ego dissolution: Temporary loss of rigid self-identity allowing new perspectives
- Therapeutic alliance: Profound sense of safety with therapist
- Emotional breakthrough: Cathartic release of held pain
Connection to addiction: At Nova Transformations, we know that trauma and addiction are deeply intertwined. Substances often numb unbearable pain. Healing trauma can eliminate the need for numbing.
3. “Mystical/Peak Experiences”
Research consistently shows: the intensity of mystical experience predicts treatment success.
Characteristics of mystical experiences:
- Unity: Feeling of oneness with universe, others, nature
- Transcendence of time/space: Dissolution of normal boundaries
- Sacredness: Deep sense of profound meaning
- Intuitive knowledge: Direct knowing beyond words
- Positive mood: Overwhelming love, peace, joy
- Ineffability: Experience beyond language
Why this helps addiction:
- Reduces fear of death (common in addiction)
- Provides sense of meaning/purpose beyond substances
- Connects to something larger than self
- Shifts values and priorities
- Often described as “spiritual awakening”
4. Reducing Default Mode Network Activity
Psychedelics quiet the “default mode network” (DMN)—brain regions active during self-referential thinking:
- Overactive DMN: Associated with rumination, depression, addiction
- Ego and self-narrative: “I’m an addict,” “I can’t change”
- Psychedelics reduce DMN activity: Temporary dissolution of rigid self-concept
- Allows new narratives: “I can be someone who doesn’t drink”
5. Enhanced Suggestibility and Therapeutic Alliance
- Psychedelic state increases openness to therapeutic suggestions
- Deepens trust and connection with therapist
- Breaks down defensive barriers
- Creates window for meaningful therapeutic work
💡 Multiple Mechanisms
Psychedelics don’t work through one pathway—they’re creating conditions for profound psychological change through neuroplasticity, trauma processing, mystical experiences, and enhanced therapy. This multi-faceted approach may explain why they help when traditional single-mechanism treatments don’t.
Which Addictions May Psychedelics Help?
| Addiction Type | Evidence Level | Which Psychedelic(s) | Status |
|---|---|---|---|
| Alcohol Use Disorder | ⭐⭐⭐⭐⭐ STRONG | Psilocybin, LSD, Ayahuasca | Multiple RCTs, 83% reduction in drinking |
| Tobacco/Nicotine | ⭐⭐⭐⭐⭐ STRONG | Psilocybin | 80% abstinence at 6 months vs. <35% standard |
| Cocaine | ⭐⭐⭐⭐ PROMISING | Psilocybin, Ketamine | Early trials positive, more data needed |
| Opioids (Heroin, Pills) | ⭐⭐⭐ EMERGING | Ibogaine, MDMA, Psilocybin | Observational data positive, RCTs ongoing |
| Methamphetamine | ⭐⭐⭐ EMERGING | Psilocybin, MDMA | Trials underway |
| PTSD (→Addiction) | ⭐⭐⭐⭐⭐ STRONG | MDMA | 67% remission, FDA approval expected 2025 |
Important Note on Treatment Approach
Psychedelic therapy is NOT standalone treatment. Successful protocols combine:
- Thorough screening
- Preparation therapy sessions
- Supervised dosing (1-3 sessions typically)
- Integration therapy (multiple sessions processing experience)
- Ongoing support (may include traditional MAT, therapy, 12-step)
Legal Status in 2025
Federal Level
Schedule I (Illegal):
- Psilocybin, LSD, MDMA, DMT, mescaline, ibogaine
- “No accepted medical use” (despite clinical evidence)
- Legal penalties for possession/distribution
- EXCEPTION: Approved clinical trials
Schedule III (Controlled but Legal in Medical Settings):
- Ketamine—already prescribed for depression
- Available at specialized clinics
FDA Breakthrough Therapy Designation:
- MDMA for PTSD (approval decision expected 2025)
- Psilocybin for treatment-resistant depression
- Accelerated approval pathway
State Level Changes
Oregon (First in Nation):
- Psilocybin therapy legalized 2023
- Licensed facilitators, supervised use
- Adults can access without doctor prescription
Colorado:
- Psilocybin and other psychedelics decriminalized/legalized
- Licensed therapy centers opening
Other states considering:
- California, Washington, Massachusetts—ballot initiatives and legislation
North Carolina:
- Psychedelics remain Schedule I
- No current legalization efforts
- Only available through clinical trials
Access Options in 2025
Legal access:
- Clinical trials: ClinicalTrials.gov lists ongoing studies—some recruiting
- Ketamine clinics: Legal and available in Charlotte area
- Oregon/Colorado therapy centers: Must travel to these states
- Research institutions: Universities conducting studies
Illegal but happening:
- Underground facilitators and “guides”
- Ayahuasca retreats (domestically and abroad)
- RISKS: No medical screening, no regulation, legal consequences, safety concerns
⚠️ Legal Reality
Possession, distribution, or use of Schedule I psychedelics outside approved research is illegal and can result in criminal charges. While we discuss the science and potential therapeutic applications, Nova Transformations does NOT provide psychedelic therapy as these substances remain federally illegal. We support changing policies based on evidence while following current law.
Who Should (and Shouldn’t) Consider Psychedelic Therapy
Potential Candidates (When Legal/Available)
Best suited for psychedelic-assisted therapy:
- Treatment-resistant addiction: Haven’t responded to MAT, therapy, rehab
- Underlying trauma: PTSD, childhood abuse, complex trauma driving substance use
- Motivated for deep psychological work: Not looking for “magic pill”
- Psychologically stable enough: Can tolerate intense experiences
- Strong support system: People to help with integration
- Open to the process: Willing to surrender control temporarily
Absolute Contraindications
Should NOT use psychedelics:
- Personal or family history of psychosis/schizophrenia
- Bipolar disorder type I (especially manic episodes)
- Active suicidal ideation without support
- Severe personality disorders (some types)
- Recent heart attack, stroke, or severe cardiovascular disease
- Uncontrolled hypertension
- Pregnancy or breastfeeding
- Seizure disorders (depending on substance)
Relative Contraindications (Require Careful Assessment)
- History of difficult psychological experiences with psychedelics
- Moderate cardiovascular issues
- Currently taking certain medications (SSRIs, MAOIs)
- Insufficient support system
- Unstable living situation
Important Screening
Legitimate psychedelic therapy requires:
- Comprehensive psychiatric evaluation
- Medical history and physical exam
- Family psychiatric history
- Current medications review
- Cardiovascular screening
- Preparation to assess psychological readiness
Risks and Controversies
1. Psychological Risks
“Bad Trips” (Challenging Experiences):
- Overwhelming anxiety, fear, paranoia
- Confronting difficult emotions/memories
- Temporary disorientation, confusion
- Mitigation: Skilled therapist support, “set and setting” optimization
- Note: Sometimes challenging experiences lead to therapeutic breakthroughs
Psychosis Risk:
- Can trigger psychotic episodes in vulnerable individuals
- Risk highest with personal/family history
- Usually temporary but can be prolonged
Hallucinogen Persisting Perception Disorder (HPPD):
- Rare condition: flashbacks, visual disturbances persist
- More common with frequent use, less with therapeutic protocols
2. Physical Risks
- Increased heart rate/blood pressure: Concern for cardiovascular disease
- Nausea/vomiting: Common with many psychedelics
- Ibogaine cardiac risks: Can cause fatal arrhythmias—requires intensive monitoring
- Generally low toxicity: Psilocybin, LSD have wide safety margins
3. The “Expectancy” Problem
- Impossible to truly blind psychedelic trials—people know when they got real drug
- >90% of patients and therapists correctly guess assignment
- Creates powerful placebo effects
- Hard to separate drug effect from expectation
4. Integration is Critical
- Psychedelic experience alone ≠ lasting change
- Must do therapeutic work to integrate insights
- Without integration, benefits may fade
- Requires ongoing therapy, lifestyle changes, support
5. Not a Panacea
- Doesn’t work for everyone
- Some people don’t have profound experiences
- Relapse still possible
- Not a replacement for comprehensive treatment
6. Access and Equity Concerns
- Currently available mainly to wealthy, white populations
- Clinical trials have limited diversity
- When legal, will likely be expensive
- Creates disparities in who can benefit
7. Potential for Misuse
- Unqualified “shamans” and facilitators
- Sexual misconduct during vulnerable states
- No regulation in underground settings
- People attempting self-treatment without support
🚨 Critical Safety Message
Psychedelic therapy is NOT something to attempt on your own or with unqualified facilitators. The powerful psychological effects require professional support, medical screening, and proper set and setting. People with certain psychiatric conditions can experience severe adverse reactions. Underground use carries serious risks including legal consequences, lack of screening, and potential harm.
Psychedelic Therapy and Traditional Treatment: Integration at Nova
At Nova Transformations in Charlotte, NC, we don’t currently provide psychedelic therapy (as these substances remain federally illegal for addiction treatment). However, we recognize the promising research and see psychedelics as potentially complementary to—not replacement for—proven addiction treatment.
Our Evidence-Based Approach
1. Medication-Assisted Treatment (MAT)
FDA-approved medications with decades of evidence:
- Buprenorphine (Suboxone): For opioid addiction
- Naltrexone (Vivitrol): For alcohol and opioid addiction
- Acamprosate: For alcohol cravings
2. Trauma-Focused Therapy
Addressing root causes that psychedelics also target:
- EMDR (Eye Movement Desensitization and Reprocessing)
- Trauma-Focused CBT
- Somatic Experiencing
- Internal Family Systems
3. Dual Diagnosis Treatment
- Treating co-occurring depression, anxiety, PTSD
- Comprehensive psychiatric care
- Addressing underlying mental health driving addiction
4. Evidence-Based Psychotherapies
- Cognitive Behavioral Therapy (CBT)
- Dialectical Behavior Therapy (DBT)
- Motivational Interviewing
- Acceptance and Commitment Therapy (ACT)
5. Holistic Approaches
Addressing mind, body, spirit:
- Mindfulness and meditation
- Yoga therapy
- Nutrition counseling
- Exercise programming
- Spiritual exploration (when desired)
6. Intensive Programs
Partial Hospitalization Program (PHP):
- 20-30 hours/week intensive treatment
- Medical monitoring and medication management
- Comprehensive therapy
Intensive Outpatient Program (IOP):
- 9-12 hours/week
- Flexible day and evening scheduling
- For working professionals and parents
The Future: Integration Model
If/when psychedelic therapy becomes legal and available, optimal treatment may combine:
- Traditional MAT for stabilization and craving reduction
- Psychedelic-assisted sessions for breakthrough trauma work (1-3 sessions)
- Ongoing integration therapy to process and apply insights
- Support groups and community
- Lifestyle interventions
- Long-term recovery support
This model recognizes that different interventions target different aspects of addiction recovery.
✨ The Nova Philosophy
We believe in meeting people where they are with the best available evidence-based treatments. While psychedelic research is exciting, proven treatments like MAT, trauma therapy, and comprehensive dual diagnosis care are available NOW and helping thousands of people achieve lasting recovery. We stay informed about emerging approaches while never losing focus on what works today.
Evidence-Based Addiction Treatment in Charlotte
Whether you’re interested in cutting-edge research or proven traditional approaches, Nova Transformations provides comprehensive addiction treatment addressing trauma, co-occurring mental health conditions, and the root causes of substance use. Our dual diagnosis program combines medication-assisted treatment, trauma-focused therapy, and holistic care tailored to your unique needs. Recovery is possible with the right support.
We accept most major insurance plans. Unfortunately, we do not accept Medicare or Medicaid at this time.
Confidential assessment available. Start your recovery journey with proven, compassionate care.
Frequently Asked Questions
No, psychedelic therapy for addiction is NOT currently legal in North Carolina or anywhere in the United States except through approved clinical research trials. Psilocybin, LSD, MDMA, DMT, mescaline, and ibogaine remain Schedule I controlled substances under federal law, meaning they are classified as having “no accepted medical use” and high abuse potential, making possession, distribution, or use illegal and subject to criminal penalties. The only exception is ketamine, which is Schedule III and can be legally prescribed by doctors for depression at specialized clinics including some in the Charlotte area. However, the legal landscape is changing with Oregon legalizing psilocybin therapy in 2023 (first state), Colorado legalizing and decriminalizing various psychedelics with licensed therapy centers opening, and the FDA granting “Breakthrough Therapy” designation to MDMA for PTSD (approval decision expected 2025) and psilocybin for treatment-resistant depression, putting them on accelerated approval pathways. Several other states including California, Washington, and Massachusetts are considering legalization through ballot initiatives and legislation, but North Carolina has no current legalization efforts and psychedelics remain Schedule I. Legal access options in 2025 include participating in clinical trials listed on ClinicalTrials.gov (some actively recruiting), traveling to Oregon or Colorado for legal psilocybin therapy, visiting ketamine clinics (legal nationwide), or enrolling in research studies at universities. Illegal but occurring options include underground facilitators and “guides” (carries risks of no medical screening, no regulation, legal consequences, and safety concerns), ayahuasca retreats domestically and abroad, and self-treatment (extremely risky). At Nova Transformations in Charlotte, we do NOT provide psychedelic therapy as these substances remain federally illegal for addiction treatment. We support evidence-based policy reform while following current law and providing proven legal treatments including medication-assisted treatment, trauma therapy, and dual diagnosis care.
Yes, clinical research published in leading medical journals demonstrates that psychedelic-assisted therapy shows remarkable efficacy for certain addictions, substantially exceeding traditional treatment success rates. For alcohol use disorder, a landmark 2022 randomized, double-blind, placebo-controlled trial published in JAMA Psychiatry with 93 participants found that two doses of psilocybin combined with 12 weeks of psychotherapy produced an 83% reduction in heavy drinking days at 32 weeks compared to placebo plus therapy, with benefits sustained through 36-week follow-up and statistical significance of p<0.001 meaning results are highly unlikely due to chance. For tobacco/nicotine addiction, Johns Hopkins research showed 80% (12 of 15 participants) had biochemically confirmed smoking abstinence at 6 months with psilocybin plus cognitive behavioral therapy, dramatically outperforming traditional cessation treatments which achieve less than 35% abstinence at 6 months, with 11 of the 12 successful participants quitting after just the first psilocybin session and benefits sustained at 12 and 30-month follow-ups. For cocaine use disorder, early University of Alabama study results report higher life satisfaction, less depression, and more abstinent days than placebo (full results pending). For PTSD which often drives addiction, MAPS Phase 3 trials found 67% of participants no longer met PTSD diagnostic criteria after three sessions of MDMA-assisted psychotherapy with benefits sustained months to years later. A 44,000-person observational study found psychedelic use associated with 27% reduced risk of opioid dependence. However, critical limitations include that most large studies are observational rather than randomized controlled trials, long-term effectiveness beyond 1-2 years is unknown, the "expectancy effect" is significant since it's impossible to blind participants (over 90% correctly guess whether they received psychedelic or placebo), psychedelic experience alone doesn't create lasting change without integration therapy and ongoing support, these treatments don't work for everyone with some people not having profound experiences, and relapse remains possible. The consistency of positive results across multiple substances (psilocybin, LSD, MDMA), multiple addictions (alcohol, tobacco, cocaine), and multiple independent research groups suggests real therapeutic potential beyond placebo effects. These aren't fringe studies—they're published in journals like JAMA, conducted at institutions like Johns Hopkins and Imperial College London, and receiving the first U.S. government funding for psychedelic research since the 1971 ban.
Psychedelics work through multiple complementary mechanisms that together create conditions for profound psychological and neurological change. First, they promote dramatic neuroplasticity—the brain’s ability to form new connections—by activating serotonin 5-HT2A receptors (in classic psychedelics like psilocybin and LSD), increasing brain-derived neurotrophic factor (BDNF) which acts as “fertilizer for the brain,” facilitating synaptic plasticity allowing new neural pathways to form, temporarily disrupting entrenched brain networks including rigid addiction circuits, and creating a neurological “reset” window where new, healthier patterns can develop—critical because addiction creates maladaptive brain circuits that are extremely difficult to change. Second, they facilitate deep trauma processing since many addictions are rooted in unprocessed trauma with MDMA reducing fear response allowing accessing traumatic memories without overwhelming distress, increased emotional openness enabling feeling and processing repressed emotions, temporary ego dissolution allowing new perspectives on self and past experiences, profound sense of safety and trust with therapist enhancing therapeutic alliance, and cathartic release of held pain. Third, they induce “mystical or peak experiences” characterized by feelings of unity/oneness with universe, transcendence of normal time/space boundaries, deep sense of sacredness and meaning, direct intuitive knowing, overwhelming positive emotions of love/peace/joy, and ineffability (beyond language), with research consistently showing that intensity of mystical experience predicts treatment success by reducing fear of death, providing sense of meaning beyond substances, connecting to something larger than self, shifting values and priorities, and often being described as “spiritual awakening.” Fourth, they reduce default mode network (DMN) activity—brain regions active during self-referential thinking and rumination—which is overactive in depression and addiction creating rigid self-narratives like “I’m an addict” or “I can’t change,” with psychedelics temporarily dissolving these rigid self-concepts allowing new narratives to form. Fifth, they enhance suggestibility and therapeutic alliance, increasing openness to therapeutic suggestions, deepening trust with therapist, breaking down defensive barriers, and creating optimal windows for meaningful therapeutic work. This multi-faceted approach targeting neuroplasticity, trauma, mystical experience, self-concept, and enhanced therapy may explain why psychedelics help when traditional single-mechanism treatments fail.
Psychedelic therapy carries significant psychological and physical risks that must be carefully considered, which is why proper medical screening and professional supervision are essential. Psychological risks include “bad trips” or challenging experiences with overwhelming anxiety, fear, paranoia, confrontation of difficult emotions or memories, and temporary disorientation—though skilled therapist support and optimized “set and setting” can mitigate these and sometimes challenging experiences lead to therapeutic breakthroughs. Psychosis risk is serious as psychedelics can trigger psychotic episodes in vulnerable individuals, with highest risk in those with personal or family history of psychosis or schizophrenia, usually temporary but can be prolonged. Hallucinogen Persisting Perception Disorder (HPPD) is rare but involves persistent flashbacks and visual disturbances, more common with frequent recreational use and less with therapeutic protocols. Physical risks include increased heart rate and blood pressure concerning for those with cardiovascular disease, nausea and vomiting common with many psychedelics, and ibogaine carrying serious cardiac risks including fatal arrhythmias requiring intensive medical monitoring, though psilocybin and LSD generally have wide safety margins and low toxicity. The “expectancy problem” is significant as it’s impossible to truly blind psychedelic trials—over 90% of patients and therapists correctly guess treatment assignment creating powerful placebo effects making it hard to separate drug effects from expectations. Integration is critical as psychedelic experience alone doesn’t equal lasting change, requiring ongoing therapeutic work to integrate insights or benefits may fade. Additional concerns include that psychedelics are not a panacea and don’t work for everyone with some people not having profound experiences and relapse still possible, access and equity issues as current availability is mainly to wealthy white populations with clinical trials having limited diversity, potential for misuse by unqualified “shamans” and facilitators, sexual misconduct during vulnerable states, no regulation in underground settings, and people attempting risky self-treatment without support. Absolute contraindications include personal or family history of psychosis/schizophrenia, bipolar disorder type I, active suicidal ideation without support, severe personality disorders, recent cardiovascular events, uncontrolled hypertension, pregnancy/breastfeeding, and seizure disorders. At Nova Transformations, we emphasize that psychedelic therapy is NOT something to attempt on your own or with unqualified facilitators, as powerful psychological effects require professional support, medical screening, and proper preparation.
The decision about psychedelic therapy should only be made after careful consideration of your individual circumstances, legal realities, available options, and in consultation with addiction and mental health professionals. Currently, psychedelic therapy for addiction is NOT legally available in North Carolina or most of the United States except through approved clinical trials, so your immediate options are limited to searching ClinicalTrials.gov for recruiting studies, considering legal ketamine therapy for depression/anxiety at Charlotte-area clinics, traveling to Oregon or Colorado where psilocybin therapy is legal, or continuing with proven evidence-based treatments like medication-assisted treatment and trauma therapy available now at Nova Transformations. You might be a good candidate IF psychedelics become legally available and you have treatment-resistant addiction that hasn’t responded to MAT, therapy, or rehab, underlying trauma (PTSD, childhood abuse) driving substance use, motivation for deep psychological work beyond looking for a “magic pill,” psychological stability to tolerate intense experiences, strong support system to help with integration, and openness to surrendering control temporarily in a therapeutic setting. You should NEVER pursue psychedelic therapy if you have personal or family history of psychosis/schizophrenia, bipolar disorder type I, active suicidal ideation, severe personality disorders, recent heart attack/stroke or cardiovascular disease, uncontrolled hypertension, pregnancy/breastfeeding, or seizure disorders. Important considerations include that legitimate psychedelic therapy requires comprehensive psychiatric evaluation, medical history and physical exam, family psychiatric history assessment, medication review, cardiovascular screening, and multiple preparation sessions, it’s NOT standalone treatment but must be combined with ongoing therapy and support, underground or self-directed use carries serious risks including lack of screening, no regulation, legal consequences, and potential psychological/physical harm, and optimal addiction treatment likely involves psychedelics as ONE tool integrated with traditional approaches rather than replacement. At Nova Transformations in Charlotte, we recommend starting with proven evidence-based treatments available today including PHP and IOP programs, MAT for alcohol and opioid addiction, trauma-focused therapies like EMDR, and dual diagnosis treatment for co-occurring mental health conditions. Call (704) 961-9322 to discuss your specific situation and treatment options.
References and Resources
- Hogea, L., et al. (2025). The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials. Medicina, 61(2), 278. DOI: 10.3390/medicina61020278
- Bogenschutz, M. P., et al. (2022). Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder. JAMA Psychiatry, 79(10), 953-962.
- Johnson, M. W., et al. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992.
- Mithoefer, M. C., et al. (2021). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 27, 1025-1033.
- Krebs, T. S., & Johansen, P. Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994-1002.
- Piper, B. J., et al. (2025). Psychedelic-assisted treatment for substance use disorder: A narrative systematic review. Addiction. DOI: 10.1111/add.16762
- Pisano, V. D., et al. (2017). The association between psychedelic use and opioid use disorders among illicit users in the United States. Journal of Psychopharmacology, 31(5), 606-613.
- Garcia-Romeu, A., et al. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088-1101.
- Multidisciplinary Association for Psychedelic Studies (MAPS). (2024). MDMA-Assisted Therapy for PTSD. Retrieved from https://maps.org/
- National Institute on Drug Abuse (NIDA). (2024). Psychedelic and Dissociative Drugs. Retrieved from https://nida.nih.gov/
Charlotte Addiction Treatment Resources:
- Nova Transformations: (704) 961-9322
- Clinical Trials: ClinicalTrials.gov (search “psychedelic addiction”)
- SAMHSA National Helpline: 1-800-662-HELP (4357)
- MAPS (Psychedelic Research): https://maps.org/
Medical and Legal Disclaimer: This article is for informational and educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Psychedelic substances including psilocybin, LSD, MDMA, DMT, mescaline, and ibogaine are Schedule I controlled substances under U.S. federal law, making possession, distribution, or use illegal outside approved research settings and subject to criminal penalties. This article discusses clinical research and therapeutic potential but does NOT advocate illegal drug use. Nova Transformations does NOT provide psychedelic therapy as these substances remain federally illegal for addiction treatment. Any use of psychedelics should only occur within legal, medically supervised clinical trials. Psychedelics carry significant risks including potential for psychological adverse events, and are absolutely contraindicated for individuals with certain psychiatric or medical conditions. Never attempt self-treatment with psychedelics. Always consult qualified healthcare providers for addiction treatment decisions. If experiencing medical or mental health emergencies, call 911 immediately.
Last Updated: November 11, 2025 | Author: Nova Transformations Clinical Research Team | Location: Charlotte, North Carolina
